The release of the latest FDA guidance documents on 21 CFR part 11 and data integrity has generated significant confusion regarding the necessary compliance measures. This is particularly evident in the field of dissolution testing. In order to alleviate this confusion, our webinar aims to provide clear insights into how these guidance documents specifically pertain to dissolution testing and outline the essential components required for meeting the compliance requirements effectively.
Related White Paper